文献速递肾癌与肾肿瘤

抗生素使用对转移性肾细胞癌全身治疗疗效的影响

Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2019-09-25

本研究分析两个队列:机构队列146例接受PD-1/PD-L1免疫检查点抑制剂(ICI)的转移性肾细胞癌(mRCC)患者,以及试验数据库队列4144例接受干扰素-α、mTOR抑制剂或VEGF靶向治疗的患者。结果显示,抗生素使用与ICI组较低的客观缓解率(ORR)和较短的无进展生存期(PFS)相关,并在干扰素组和既往细胞因子治疗的VEGF靶向治疗组中与较差的总生存期(OS)相关。结论提示抗生素使用可能降低mRCC免疫治疗疗效,需合理使用抗生素。

要点

  • 抗生素使用与ICI治疗mRCC患者较低ORR和较短PFS独立相关。
  • 抗生素使用在干扰素或既往细胞因子VEGF-TT治疗患者中与较差OS相关。
  • mTOR抑制剂或未接受既往细胞因子的VEGF-TT患者中未见抗生素对OS的显著影响。

核心结论

  • 抗生素使用似乎降低mRCC免疫治疗方案的疗效。
  • 调节肠道菌群可能对优化ICI治疗患者的结局有重要作用。

研究设计与样本

  • 分析机构队列146例接受PD-1/PD-L1免疫检查点抑制剂的mRCC患者。
  • 分析试验数据库队列4144例接受干扰素-α(n=510)、mTOR抑制剂(n=660)或VEGF靶向治疗(n=2974)的II/III期临床试验患者。
  • 抗生素使用定义为抗癌治疗开始前8周至开始后4周内使用。
  • 采用Cox回归分析抗生素使用与PFS和OS的关联,校正已知预后因素包括IMDC风险因素。

主要发现

  • 机构队列中,抗生素使用者(n=31,21%)的ORR为12.9%,非使用者为34.8%(p=0.026)。
  • 机构队列中,抗生素使用者相比非使用者PFS更短(校正HR=1.96,95%CI 1.20-3.20,p=0.007)。
  • 试验数据库队列中,抗生素使用(n=709,17%)对接受干扰素治疗患者的OS有不利影响(HR=1.62,95%CI 1.13-2.31,p=0.008)。
  • 试验数据库队列中,抗生素使用对接受VEGF-TT且有既往细胞因子治疗患者的OS有不利影响(HR=1.65,95%CI 1.04-2.62,p=0.033)。
  • 试验数据库队列中,抗生素使用对接受mTOR抑制剂或VEGF-TT无既往细胞因子治疗患者的OS无显著影响。

关键数值与推荐

  • 机构队列总体ORR为30%,PFS为7.2个月,1年OS率为77%。
  • 抗生素使用定义为抗癌治疗开始前8周至开始后4周内使用。

临床怎么用

  • 在mRCC患者开始免疫治疗前及治疗早期,应审慎评估抗生素使用的必要性。
  • 对于接受干扰素或既往细胞因子后VEGF-TT治疗的患者,也应关注抗生素使用对生存的潜在不利影响。

局限性

  • 回顾性研究设计。
  • 关于合并用药及抗生素使用指征和疗程的细节有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibiotic use alters commensal gut microbiota, which is a key regulator of immune homeostasis. OBJECTIVE: To investigate the impact of antibiotic use on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with systemic agents. DESIGN, SETTING, AND PARTICIPANTS: We analyzed two cohorts: an institutional cohort (n=146) receiving programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-based immune checkpoint inhibitors (ICIs) and a trial-database cohort (n=4144) receiving interferon-α (n=510), mammalian target of rapamycin (mTOR) inhibitors (n=660), and vascular endothelial growth factor targeted therapies (VEGF-TT; n=2974) on phase II/III clinical trials. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: The association of antibiotic use (defined as use from 8 wk before to 4 wk after the initiation of anticancer therapy) with progression-free survival (PFS) and overall survival (OS) was evaluated using Cox regression, adjusted for known prognostic factors including International Metastatic RCC Database Consortium risk factors. RESULTS AND LIMITATIONS: Most patients were male, had clear cell histology, and were at an intermediate risk. Overall, in the institutional cohort, objective response rate (ORR) was 30%, PFS was 7.2 mo, and 1-yr OS was 77%. Antibiotic users (n=31, 21%) had a lower ORR (12.9% vs 34.8%, p=0.026) and shorter PFS (adjusted hazard ratio [HR]=1.96, 95% confidence interval [CI] 1.20-3.20, p=0.007) than antibiotic nonusers. In the trial-database cohort, antibiotic use (n=709, 17%) adversely impacted OS in patients treated with interferon (HR=1.62, 95% CI 1.13-2.31, p=0.008) or with VEGF-TT and prior cytokines (HR=1.65, 95% CI 1.04-2.62, p=0.033), but not patients treated with mTOR inhibitors or VEGF-TT without prior cytokines. Limitations include retrospective design, and limited details regarding concomitant medications and antibiotic indication/duration. CONCLUSIONS: Antibiotic use appears to reduce the efficacy of immunotherapy-based regimens in mRCC. The modulation of gut microbiota may play an important role in optimizing outcomes of patients treated with ICIs. PATIENT SUMMARY: We evaluated metastatic renal cell carcinoma patients and found that those who were treated with immunotherapy had worse outcomes if they also received antibiotics at the start of treatment. This study highlights the importance of judicious antibiotic use.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lalani AA, Xie W, Braun DA, et al. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2019. PMID: 31562048. doi:10.1016/j.euo.2019.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。